RECOVER-TLC Therapeutics

As an important first step of the RECOVER-TLC initiative, an online portal was launched on Sept. 30, 2024, to help identify promising therapeutic approaches for treating Long COVID. Submissions to the portal can include proposed drugs, devices, or other therapeutic or biologic agents or interventions targeted at alleviating symptoms associated with Long COVID. All individuals – patients, caregivers, scientists, and the pharmaceutical and biotech industries – have been encouraged to share their ideas.

Each week, FNIH retrieves all new submissions from the portal and stratifies them into the following therapeutic categories:

• Drug (with further division into one of five categories: immunomodulatory, neurological agents, antiviral, host-directed, or other)
• Nutrition and diet
• Device
• Complementary and integrative health
• Manual and physical therapies

The first wave of review for submitted antiviral agents took place on Dec. 16, 2024. The next wave of antiviral review is scheduled for early January. Invitations for working group members to review agents that fall under the additional categories outlined above are in progress, and the first round of agent review for these submissions is slated for early to mid-January 2025.

Portal submission sources

Here is information about who is making portal submissions. All the data below reflects submissions through Dec. 10, 2024:

Most of the portal submissions have come from patients (69%), academia (11%), and caregivers (8%). Additional ideas have come from companies (6%), research institutes (4%), and others (2%).

Submission categories

Here is the breakdown on the types of therapy ideas we have been receiving.

Sixty-nine percent of the portal submissions fall into the drug category, supplemented by nutrition and diet (12%), and manual and physical therapies (8%). Other submissions include complementary and integrative health (6%), and devices (5%).

List of therapeutics submitted through the portal

In all, over 290 agents or combinations of agents have been received through the portal. At least 40 of those are already involved in clinical trials. The full list of submissions through Dec. 17, 2024, is below: